TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04025216
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
Study: NCT03052205
Drug: IMO-2125
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
Study: NCT02873689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole placebo-matching capsules
Study: NCT00238862
Drug: Autologous serum/BSS 20%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00907257
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.04% tretinoin gel
Study: NCT01152671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT01152671
Drug: RO5024048
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT04361656
Drug: PEG-ELS current standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for inpatient colonoscopy
Study: NCT04016974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily throughout the treatment period (day 1 to 84)
Study: NCT03531281
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01762891
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.
Study: NCT01762891
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.
Study: NCT01762891
Drug: Rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.
Study: NCT01762891
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills were given during 15 days by oral rout as one of the four interventions.
Study: NCT00679627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00641563
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of remifentanil
Study: NCT04059003
Drug: Taxanes or/and anthracycline-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.
Study: NCT03300115
Drug: AC0010
Approvals — FDA: no, EMA: no, PMDA: no
Description: After subjects prove eligible after screening and are enrolled, they are given AC0010 300 mg Bid (the two doses are advised to be administered at an interval of 12 hours), receive evaluation of safety indicators every 3 weeks, efficacy evaluation every 6 weeks until disease progression or intolerable toxicities or withdrawal from the trial. (If the investigator suspects disease progression, CT or MRI may be performed in advance; if the patient does not have disease progression, subsequent efficacy evaluation will proceed still according to the protocol).
Study: NCT01886378
Drug: UX007
Normalized name: UX007
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02039453
Drug: fentanyl doses
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl doses 50μg (37.5kg to 62.5kg), 75μg (62.5kg to 87.5kg), 100μg (\>87.5kg), single use Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
Study: NCT03255941
Drug: Sayana Press
Normalized name: garden cress sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
Study: NCT00372060
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 12 weeks
Study: NCT01285609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01271647
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: granules,18g per time,two times per day,six months
Study: NCT02053103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 0 mg, twice daily, 6 weeks
Study: NCT03994380
Drug: RhDNAse Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNAse 2.5 mg nebulizer daily for 4 weeks
Study: NCT03056989
Drug: SPX-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation solution twice daily for 7 days.
Study: NCT04694092
Drug: Standard approach to heart rate control
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heart rate control with intravenous or oral beta-blockers and/or antiarrhythmic in combination with digoxin
Study: NCT00657111
Drug: CS-8958 formulated as dry powder
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-8958, formulated as a dry-powder and will be administered from capsules containing 5 mg CS-8958 and lactose to 25 mg (placebo) inserted into a FlowCaps inhaler device.
Study: NCT00386594
Drug: 852A
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02726178
Drug: Advil® Pediatric drops for infants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
Study: NCT02726178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
Study: NCT02821390
Drug: Nepafenac Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop instilled to the eye's cul de sac prior to the intravitreal injection.
Study: NCT02821390
Drug: Placebo (Artificial Tears)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop instilled to the eye's cul de sac prior to the intravitreal injection
Study: NCT04285229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01536015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency: One patch applied every 24 hours~Duration: 10 weeks
Study: NCT01668667
Drug: GSK1838262 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: GSK1838262 600 mg/day Comparison of 3 doses
Study: NCT01668667
Drug: GSK1838262 450 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: GSK1838262 450 mg/day Comparison of 3 doses
Study: NCT01668667
Drug: GSK1838262 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: GSK1838262 300 mg/day Comparison of 3 doses
Study: NCT01668667
Drug: GSK1838262 Placebo match
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
Study: NCT02633579
Drug: Erythromycin with atropine
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous administration of erythromycin with saline
Study: NCT02951364
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg tablet administered orally once daily
Study: NCT02086799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
Study: NCT04729140
Drug: Doxycycline Tablets
Normalized name: Doxycycline Tablets
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
Study: NCT04729140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
Study: NCT02787304
Drug: SHP626
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion
Study: NCT02787304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01852955
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure
Study: NCT01912976
Drug: Er:YAG AFL-PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
Study: NCT01912976
Drug: MAL-PDT
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
Study: NCT00648180
Drug: Doxycycline Monohydrate Tablets 100 mg
Normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg, single dose fed
Study: NCT01281969
Drug: Gamunex Intravenous Immunoglobulin
Normalized name: immunoglobulin G Injection [Gamunex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 gm/kg total, IV (in the vein), over 2 days
Study: NCT01281969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline, IV (in the vein), over 2 days
Study: NCT03075410
Drug: GSK3036656
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.
Study: NCT03075410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
Study: NCT00648180
Drug: Adoxa Tablets 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, single dose fed
Study: NCT02763787
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
Study: NCT04539418
Drug: Vitamin K 2
Normalized name: vitamin K 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be monitored during the whole protocol.
Study: NCT02763787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo
Study: NCT02986828
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.
Study: NCT00347867
Drug: Viagra administration in IUGR/PET pregnancies
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04123873
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg x 4 p.o.
Study: NCT02644044
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
Study: NCT01477801
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard guideline based therapy plus placebo
Study: NCT01198002
Drug: LY2127399
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Subcutaneously (SC)
Study: NCT01198002
Drug: Placebo Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01198002
Drug: Placebo Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01198002
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate is a background therapy.
Study: NCT00048152
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00048152
Drug: mycophenolate mofetil [CellCept]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g po bid
Study: NCT02035644
Drug: Jinlida granules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02035644
Drug: placebo granules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04123873
Drug: Placebo oral capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. x 4
Study: NCT04123873
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV x 1
Study: NCT02184819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
Study: NCT01782326
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
Study: NCT01782326
Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
Study: NCT02278575
Drug: Atenativ
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous transfusion
Study: NCT00820196
Drug: Nexagon®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00820196
Drug: Nexagon® vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01613560
Drug: AI adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
Study: NCT01613560
Drug: AI+chemotherapy adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
Study: NCT02046538
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
Study: NCT02559817
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00956436
Drug: BIIB022
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Q3W
Study: NCT00950222
Drug: Imipenem/Amikacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will received as empirical therapy for VAP imipenem associated with amikacin.
Study: NCT00775463
Drug: treprostinil diethanolamine
Normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
Study: NCT00775463
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00589238
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00589238
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03198182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT03224351
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEZ/IVA fixed-dose combination tablet for oral administration.
Study: NCT03224351
Drug: Placebo (matched to VX-659/TEZ/IVA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-659 and TEZ/IVA.
Study: NCT03979066
Drug: PEGPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
Study: NCT02189668
Drug: Antibiotics only (Zosyn then Augmentin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
Study: NCT01299558
Drug: GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose of GW642444 (55mcg)
Study: NCT03389893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
Study: NCT02301715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo contained all inactive ingredients except for the neuropeptide. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
Study: NCT00455286
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02448719
Drug: TAK-792 30 mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-792 30 mg placebo was administered in the morning after a fast.
Study: NCT02448719
Drug: TAK-792 250 mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-792 250 mg placebo was administered in the morning after a fast.
Study: NCT02448719
Drug: TAK-792 500 mg placebo
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.
Study: NCT02448719
Drug: TAK-792 750 mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-792 750 mg placebo was administered in the morning after a fast.
Study: NCT00857506
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: 370 Mega Becquerel (10 mCi)
Study: NCT02448719
Drug: TAK-792 1250 mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-792 1250 mg placebo was administered in the morning after a fast.
Study: NCT01851954
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV clarithromycin infusion
Study: NCT03788083
Drug: Trimix
Normalized name: Nutrimix Mac Vented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral TriMix injection
Study: NCT03788083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral placebo injection
Study: NCT00055601
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 15, 16, and 17; Consolidation: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 8, 9, and 10.
Study: NCT00475371
Drug: MKC253 Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation powder
Study: NCT01149356
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01075048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Study: NCT00989131
Drug: Paclical®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments.
Study: NCT00989131
Drug: Taxol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments.
Study: NCT04149340
Drug: Cataract surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
Study: NCT01047943
Drug: Topical application of STA-21 ointment for treatment of psoriasis
Normalized name: Retinoids for treatment of psoriasis
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00284817
Drug: MEDI-522
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
Study: NCT00284817
Drug: MEDI-522
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
Study: NCT00284817
Drug: MEDI-522
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
Study: NCT00284817
Drug: MEDI-522
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
Study: NCT00284817
Drug: MEDI-522
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
Study: NCT03818685
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Radiotherapy will be maintained in each Arm.